Author

Keri Yang

Institution: BeOne Medicines (Switzerland)

Observed institution: BeOne Medicines (Switzerland)

OpenAlex ID: A5124453869

Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia

2026 · Sikander Ailawadhi, Swetha Challagulla, et al. · Expert Review of Hematology · 2

Real-world impact of atrial fibrillation (AFib) on cardiovascular (CV) outcomes and healthcare resource utilization (HCRU) in patients with chronic lymphocytic leukemia (CLL).

2026 · Michael Fradley, Daniel Addison, et al. · Journal of Clinical Oncology

Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma

2026 · Javier Pinilla-Ibarz, Mei Xue, et al. · Expert Review of Hematology

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia

2026 · Mazyar Shadman, Asher Chanan-Khan, et al. · Future Oncology

Works count: 4

Citation count: 2

H-index: 1

I10-index: